Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589772494> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2589772494 abstract "2047 Background: To determine the safety of the mTOR inhibitor everolimus (RAD001) administered daily with concurrent radiation and temozolomide in newly diagnosed glioblastoma patients. Methods: Everolimus was administered daily with concurrent radiation (60 Gy in 30 fractions) and temozolomide (TMZ) (75 mg/m 2 /day). Everolimus was escalated from 2.5 (Dose Level 1), to 5 (Dose Level 2), to 10 mg/day (Dose Level 3). Maintenance TMZ was delivered at 150-200 mg/m 2 on days 1 to 5 every 28 days for up to 12 cycles with concurrent everolimus at the previously established daily dose of 10 mg/day. Dose escalation continued if a dose level produced DLTs in ≤ 2 of the first 6 evaluable patients. Results: Between October 28, 2010 and July 2, 2012, the Radiation Therapy Oncology Group (RTOG) 0913 protocol initially registered a total of 35 patients, with 25 patients successfully meeting enrollment criteria, receiving drug and evaluable for toxicity. Everolimus was successfully escalated to the predetermined MTD of 10 mg/day. Two of the first 6 eligible patients experienced a DLT at each dose level. DLTs included: gait disturbance, febrile neutropenia, rash, fatigue, thrombocytopenia, hypoxia, ear pain, headache, and mucositis. Other common toxicities were Grade 1/2 hypercholesterolemia and hypertriglyceridemia. At the time of analysis, there was one death reported, which was attributed to tumor progression. Conclusions: Daily oral everolimus (10 mg) combined with both concurrent radiation therapy and TMZ followed by maintenance TMZ, is well tolerated, with an acceptable toxicity profile. A phase II randomized clinical trial with mandatory correlative biomarker analysis is currently underway, designed to both determine the efficacy of this regimen and identify molecular determinants of response. Supported by RTOG U10 CA21661 and CCOP U10 CA37422 grants from NCI and Novartis. Clinical trial information: NCT01062399." @default.
- W2589772494 created "2017-03-03" @default.
- W2589772494 creator A5014074083 @default.
- W2589772494 creator A5021656597 @default.
- W2589772494 creator A5031142519 @default.
- W2589772494 creator A5038585908 @default.
- W2589772494 creator A5050392689 @default.
- W2589772494 creator A5057536092 @default.
- W2589772494 creator A5061224035 @default.
- W2589772494 creator A5080119679 @default.
- W2589772494 date "2013-05-20" @default.
- W2589772494 modified "2023-09-26" @default.
- W2589772494 title "RTOG 0913: A phase I study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma." @default.
- W2589772494 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.2047" @default.
- W2589772494 hasPublicationYear "2013" @default.
- W2589772494 type Work @default.
- W2589772494 sameAs 2589772494 @default.
- W2589772494 citedByCount "0" @default.
- W2589772494 crossrefType "journal-article" @default.
- W2589772494 hasAuthorship W2589772494A5014074083 @default.
- W2589772494 hasAuthorship W2589772494A5021656597 @default.
- W2589772494 hasAuthorship W2589772494A5031142519 @default.
- W2589772494 hasAuthorship W2589772494A5038585908 @default.
- W2589772494 hasAuthorship W2589772494A5050392689 @default.
- W2589772494 hasAuthorship W2589772494A5057536092 @default.
- W2589772494 hasAuthorship W2589772494A5061224035 @default.
- W2589772494 hasAuthorship W2589772494A5080119679 @default.
- W2589772494 hasConcept C126322002 @default.
- W2589772494 hasConcept C143998085 @default.
- W2589772494 hasConcept C2776194525 @default.
- W2589772494 hasConcept C2776694085 @default.
- W2589772494 hasConcept C2777389519 @default.
- W2589772494 hasConcept C2779699572 @default.
- W2589772494 hasConcept C2780964509 @default.
- W2589772494 hasConcept C29730261 @default.
- W2589772494 hasConcept C502942594 @default.
- W2589772494 hasConcept C509974204 @default.
- W2589772494 hasConcept C71924100 @default.
- W2589772494 hasConceptScore W2589772494C126322002 @default.
- W2589772494 hasConceptScore W2589772494C143998085 @default.
- W2589772494 hasConceptScore W2589772494C2776194525 @default.
- W2589772494 hasConceptScore W2589772494C2776694085 @default.
- W2589772494 hasConceptScore W2589772494C2777389519 @default.
- W2589772494 hasConceptScore W2589772494C2779699572 @default.
- W2589772494 hasConceptScore W2589772494C2780964509 @default.
- W2589772494 hasConceptScore W2589772494C29730261 @default.
- W2589772494 hasConceptScore W2589772494C502942594 @default.
- W2589772494 hasConceptScore W2589772494C509974204 @default.
- W2589772494 hasConceptScore W2589772494C71924100 @default.
- W2589772494 hasLocation W25897724941 @default.
- W2589772494 hasOpenAccess W2589772494 @default.
- W2589772494 hasPrimaryLocation W25897724941 @default.
- W2589772494 hasRelatedWork W139185831 @default.
- W2589772494 hasRelatedWork W1992291788 @default.
- W2589772494 hasRelatedWork W2040084015 @default.
- W2589772494 hasRelatedWork W2046809770 @default.
- W2589772494 hasRelatedWork W2049078873 @default.
- W2589772494 hasRelatedWork W2055786882 @default.
- W2589772494 hasRelatedWork W2069377117 @default.
- W2589772494 hasRelatedWork W2071570552 @default.
- W2589772494 hasRelatedWork W2073680052 @default.
- W2589772494 hasRelatedWork W2118691735 @default.
- W2589772494 hasRelatedWork W2121104870 @default.
- W2589772494 hasRelatedWork W2146357043 @default.
- W2589772494 hasRelatedWork W2258691730 @default.
- W2589772494 hasRelatedWork W2313246394 @default.
- W2589772494 hasRelatedWork W2325786239 @default.
- W2589772494 hasRelatedWork W2359261442 @default.
- W2589772494 hasRelatedWork W3032799441 @default.
- W2589772494 hasRelatedWork W3033556583 @default.
- W2589772494 hasRelatedWork W3064873124 @default.
- W2589772494 hasRelatedWork W3088028491 @default.
- W2589772494 isParatext "false" @default.
- W2589772494 isRetracted "false" @default.
- W2589772494 magId "2589772494" @default.
- W2589772494 workType "article" @default.